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Abstract: 
 
Food–drug interaction studies are critical to evaluate appropriate dosing, timing, and formulation 
of new drug candidates. These interactions often reflect prandial-associated changes in the extent 
and/or rate of systemic drug exposure. Physiologic and physicochemical mechanisms underlying 
food effects on drug disposition are well-characterized. However, biochemical mechanisms 
involving drug metabolizing enzymes and transport proteins remain underexplored. Several 
plant-derived beverages have been shown to modulate enzymes and transporters in the intestine, 
leading to altered pharmacokinetic (PK) and potentially negative pharmacodynamic (PD) 
outcomes. Commonly consumed fruit juices, teas, and alcoholic drinks contain phytochemicals 
that inhibit intestinal cytochrome P450 and phase II conjugation enzymes, as well as uptake and 
efflux transport proteins. Whereas myriad phytochemicals have been shown to inhibit these 
processes in vitro, translation to the clinic has been deemed insignificant or undetermined. An 
overlooked prerequisite for elucidating food effects on drug PK is thorough knowledge of 
causative bioactive ingredients. Substantial variability in bioactive ingredient composition and 
activity of a given dietary substance poses a challenge in conducting robust food–drug 
interaction studies. This confounding factor can be addressed by identifying and characterizing 
specific components, which could be used as marker compounds to improve clinical trial design 
and quantitatively predict food effects. Interpretation and integration of data from in vitro, in 
vivo, and in silico studies require collaborative expertise from multiple disciplines, from botany 
to clinical pharmacology (i.e., plant to patient). Development of more systematic methods and 
guidelines is needed to address the general lack of information on examining drug–dietary 
substance interactions prospectively. 
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Article: 
 
1. Introduction 
 
The impact of food on successful delivery of promising new drug candidates via the oral route 
poses a major challenge during drug development. The influence of dietary substances on drug 
disposition depends on numerous variables, ranging from physicochemical properties of the drug 
to postprandial changes in the gastrointestinal (GI) tract (Charman et al., 1997, Custodio et al., 
2008). Components of the diet that modulate intestinal cytochrome P450 and phase II 
conjugation enzymes, as well as uptake and efflux transport proteins, constitute increasingly 
recognized contributors to food effects on drug disposition (Rodríguez-Fragoso et al., 2011). 
Many dietary substances or food ingredients derived from botanical sources have been shown to 
inhibit these processes in vitro, but translation to the clinic has been inconclusive or considered 
irrelevant (Farkas & Greenblatt, 2008). Understanding the mechanisms by which these dietary 
substances alter drug PK and PD outcomes is critical to assess clinical significance and 
management. 
 
Prediction of PK properties of new drug candidates entering clinical trials can be an arduous, 
sometimes elusive, task. The added complexity of food effects increases such difficulty. Robust 
guidelines on the evaluation of potential dietary substance–drug interactions are lacking (Abdel-
Rahman et al., 2011). Clinical studies often are difficult to compare, inconclusive, and/or fail to 
meet strict criteria required to make definitive clinical and regulatory recommendations. 
Commercially available modeling and simulation software can be a valuable tool to evaluate and 
predict, quantitatively, potential dietary substance–drug interactions. A key contributing factor to 
predictive success is a thorough knowledge of the causative ingredient(s) contained in the dietary 
substance. Identification, characterization, and validation of specific bioactive components as 
marker compounds can guide appropriate clinical trial design. Such studies enable development 
and validation of PK–PD models describing the relationship between a given dietary substance 
and drug of interest. The current review provides an update on dietary substance–drug interaction 
research, addresses challenges and potential solutions regarding the conduct and interpretation of 
associated studies, and discusses in silico strategies for predicting food effects. 
 
2. Food–drug interactions 
 
2.1. Definition 
 
A food–drug interaction is the consequence of a physical, chemical, or physiologic relationship 
between a drug and a product consumed as food or a nutrient present in a botanically-derived 
food or dietary supplement (Santos and Boullata, 2005, Genser, 2008). Such an interaction may 
manifest clinically as compromised health status due to altered PK and/or PD of the drug or 
dietary substance. Although dietary substances are regulated as food or dietary/herbal 
supplements, bioactive constituents in these substances can act like “perpetrator” drugs. That is, 
a dietary substance can increase systemic “victim” drug exposure (AUC), increasing the risk of 
adverse events and toxicity, or decrease systemic victim drug exposure, leading to therapeutic 
failure (Santos & Boullata, 2005). A lack of an interaction may be due to insufficient 
concentration(s) of causative ingredients at the enzyme or transporter active site, metabolism of 
causative ingredients to inactive products, or transport of causative ingredients out of target cells 
(e.g., enterocyte, hepatocyte). Underlying mechanisms by which food exerts such effects 
generally include physiologic, physicochemical, and/or biochemical processes (Fleisher et al., 
1999). Elucidation of these processes in relevant organ systems is essential to resolve issues 
related to formulation, dosing schedule, and optimal pharmacotherapeutic strategies (Li et al., 
2002, Lentz, 2008, Parrott et al., 2009). 
 
2.2. Regulatory guidelines 
 
Potential clinically significant implications of food–drug interactions are recognized by 
worldwide regulatory agencies, each with specific guidelines. A guidance issued by the United 
States Food and Drug Administration (FDA) in 2002 provided recommendations on the design 
and conduct of food effect and fasted/fed state studies (http://www.fda.gov/cder/guidance). 
High-calorie (~800–1000 cal) and high-fat (~50% of total caloric content) test meals represent 
the ‘worst-case scenario’ and are expected to alter maximally GI physiology and subsequent 
systemic drug availability. Although examination of the effects of food consumption on the PK 
of drugs is a standard practice, the issue has become greater than “take with or without food” 
since a variety of specific dietary substances has been shown to alter systemic drug availability. 
Evaluation of the underlying mechanism(s) can ultimately lead to firm conclusions required to 
make informed clinical and regulatory decisions or guidelines. 
 
3. Underlying mechanisms of food effect on drug exposure and response 
 
3.1. Physiologic and physicochemical mechanisms 
 
Dietary substances can alter drug absorption, distribution, metabolism, and/or excretion (ADME) 
via physiologic and physicochemical mechanisms. Physiologic/mechanical mechanisms include 
delayed gastric emptying, stimulated/increased bile or splanchnic blood flow, and GI pH or flora 
changes. Alterations of such processes can lead to reduced absorption of some drugs (e.g., 
penicillins, angiotensin-converting enzyme inhibitors) (Singh, 1999). Physicochemical 
mechanisms include binding of the drug by the food. For example, enteral nutrition formulas are 
incompatible with the antiepileptic agent, phenytoin, which can bind to proteins and salts in 
enteral formulations, resulting in reduced phenytoin absorption and potentially inadequate 
seizure control (Lourenço, 2001). Some tetracyclines and fluoroquinolones can bind to divalent 
cation-containing products (e.g., calcium in dairy), resulting in reduced drug absorption (Polk, 
1989, Jung et al., 1997) and potential therapeutic failure. High fat meals can increase drug 
absorption by improving solubility, such as with some antiretroviral protease inhibitors (e.g., 
saquinavir, atazanavir) (Plosker and Scott, 2003, Le Tiec et al., 2005). Other examples are 
discussed comprehensively in several sources (Wolinsky and Williams, 2002, McCabe et al., 
2003, Boullata and Armenti, 2004, Meckling, 2007, Stargrove et al., 2008). 
 
3.2. Biochemical mechanisms 
 
Biochemical mechanisms include interference with co-factor formation or function, potentiation 
of drug PD, and modification of drug metabolizing enzyme/transporter function by the dietary 
substance (Chan, 2002). For example, vitamin K-rich foods interfere with co-factor function and 
should be consumed cautiously with the anticoagulant, warfarin, as they can disrupt vitamin K 
metabolism and increase risk of bleeding or clot formation (Holbrook et al., 2005). Isoniazid and 
monoamine oxidase inhibitors, used to treat tuberculosis and depression, respectively, inhibit the 
breakdown of endogenous and dietary amines; a tyramine-rich diet can potentiate a hypertensive 
crisis (Brown et al., 1989, Self et al., 1999). Foods consumed as beverages account for a very 
high proportion of dietary antioxidant intake (Pulido et al., 2003). Growing evidence supporting 
cardioprotective benefits promotes moderate consumption as part of a healthy lifestyle (Kaplan 
and Palmer, 2000, Guilford and Pezzuto, 2011). However, certain beverages contain substances 
that can influence drug disposition via modulation of drug metabolizing enzymes and 
transporters in the intestine. 
 
Several studies have assessed the effect of wine, beer, fruit juices, tea, and specific constituents 
therein on CYP activity in vitro, but clinical studies are limited. These beverages have become 
highly recommended supplements to routinely prescribed and over-the-counter drugs and/or as 
monotherapy for prevention, treatment, and maintenance of common diseases. Some ingredients 
identified in fruit juices, teas, and alcoholic beverages have been shown to inhibit intestinal 
metabolism and active apical efflux/uptake processes in vitro and in vivo. Inhibition of 
metabolism and active efflux would be expected to increase, whereas inhibition of active uptake 
would be expected to decrease, systemic drug exposure. These biochemical mechanisms, 
specifically with respect to the intestine, are highlighted in the current review. Examples of other 
dietary substance–drug interactions are detailed in several sources (Wolinsky and Williams, 
2002, McCabe et al., 2003, Boullata and Armenti, 2004, Meckling, 2007, Stargrove et al., 2008). 
 
 
Figure 1. Schematic representation of enterocytes. Like drugs, dietary substances can alter 
systemic “victim” drug exposure by inhibiting enteric transporter-mediated uptake and/or efflux, 
as well as phase I and II metabolism. BCRP: breast cancer resistance protein, CYP: cytochrome 
P450, MRP: multidrug resistance-associated protein, OATP: organic anion-transporting 
polypeptide, P-gp: P-glycoprotein, SULT: sulfotransferase, UGT: UDP-glucuronosyltransferase. 
 
4. Inhibition of intestinal biochemical processes 
 
The clinical significance of the intestine as a barrier to drug absorption and as a site for drug–
drug interactions (DDIs) is recognized widely (Tidball, 1971). Successful delivery of an oral 
drug to the target site encompasses a complex multifactorial process, requiring the identification 
of factors and mechanisms involved in optimal formulation design and the subsequent effects of 
interactions with the GI environment. A prime hindrance to drug absorption is the variety of drug 
metabolizing enzymes and transport proteins in the enterocyte that detoxify, bioactivate, and 
shuttle xenobiotics (Fig. 1). Environmental variables such as polypharmacy and diet add to the 
challenge of achieving therapeutic efficacy while avoiding toxicity or treatment failure (McCabe, 
2004). 
 
Purported health benefits of certain botanical products have led to their promotion as 
complements (or alternatives) to drug therapy (Espin et al., 2007). The popular consumption of 
fruit juices, teas, and alcoholic drinks is attributed not only to taste and nutritive value but also to 
increased awareness of the pharmacologic (e.g., antioxidant) effects of specific constituents 
(Gruenwald, 2009). However, in parallel, a growing number of in vitro and in vivo studies have 
demonstrated inhibitory, potentially detrimental, effects on enzymes and transporters involved in 
drug disposition, particularly those in the intestine, the primary portal for drugs and dietary 
substances (Huang et al., 2008). The proceeding sections describe the latest findings in 
beverage–drug interaction research. 
 
4.1. Phase I metabolism 
 
4.1.1. Cytochrome P450 3A 
 
The cytochromes P450 (CYPs) are the predominant phase I enzymes involved in drug 
metabolism (Shen et al., 1997). Of the CYPs expressed in the intestine, the CYP3A subfamily is 
the most abundant and has been established to influence drug disposition in vivo (Lin and Lu, 
2001, Paine et al., 2006). CYP3A is composed largely of CYP3A4 and CYP3A5 in adults. 
Enteric CYP3A4 is located primarily in the villous tips of the enterocytes lining the upper and 
middle third of the intestine (duodenum to distal jejunum) (Thummel & Wilkinson, 1998). 
CYP3A is responsible for the oxidative metabolism of more than half of pharmaceutical agents 
on the market (Gibbs & Hosea, 2003). The effects of several fruit juices on CYP3A expression 
and activity have been studied extensively in vitro and in human participants. Specific inhibitory 
ingredients in some fruit juices have been identified and characterized. In contrast, data on 
enteric CYP3A inhibition by teas and alcoholic beverages (e.g., wine, beer) are less abundant 
and the clinical significance remains to be determined. 
 
4.1.1.1. Grapefruit juice (GFJ) 
 
Juice prepared from grapefruit (Citrus × paradisi Macfad.) is one of the most exhaustively 
studied dietary substances shown to inhibit enteric metabolism of numerous CYP3A substrates 
(Mertens-Talcott et al., 2006, Seden et al., 2010, Hanley et al., 2011). GFJ can enhance systemic 
drug exposure by inhibiting CYP3A-mediated pre-systemic (first-pass) metabolism in the 
intestine (Paine & Oberlies, 2007). Inhibition is localized primarily in the gut, as demonstrated 
by a lack of effect on the elimination half-life of orally administered substrates and on the PK of 
intravenously administered substrates (Kupferschmidt et al., 1995). The increase in systemic 
drug exposure can be sufficient to produce adverse events, such as muscle pain with some statins 
and severe hypotension with some calcium channel blockers (Saito et al., 2005). Compounds 
known as furanocoumarins (e.g., 6′,7′-dihydroxybergamottin, bergamottin), in aggregate, have 
been established as major mediators of the ‘GFJ effect’ in humans (Paine et al., 2006). Modes of 
intestinal CYP3A inhibition include reversible and mechanism-based (Schmiedlin-Ren et al., 
1997, Paine et al., 2004, Paine et al., 2005), as well as degradation of the protein (Lown et al., 
1997). Research on the impact of GFJ on drug disposition and response is reported and updated 
frequently. Table 1 summarizes the design and results of GFJ–drug clinical studies since the 
authors' previous review was published in 2010 (Won et al., 2010). 
 
Two unusual case reports on the effect of GFJ on CYP3A substrates administered intravenously 
were reported recently. One involved a 52 year-old Caucasian woman diagnosed with a locally 
advanced unresectable esophageal squamous cell carcinoma (Valenzuela et al., 2011). She began 
a docetaxel-containing (40 mg/m2 biweekly) chemotherapy regimen. After the first treatment 
cycle, the AUC of docetaxel was higher (65%) compared to typical values. In parallel, 
hematologic toxicity, particularly a decrease in neutrophil count (by 71%), was observed. After 
interviewing the patient and reviewing her medication history, the investigators concluded that 
GFJ was responsible for the decrease in docetaxel clearance. She reported drinking GFJ 
(250 mL) daily for more than three months. Two weeks after she was advised to cease drinking 
GFJ, docetaxel was administered. Relative to the first cycle, docetaxel AUC was reduced by 
60%, approximating the AUC target value. The other case involved an 83-year-old woman with 
a history of acute myocardial infarction and paroxysmal atrial fibrillation (Agosti et al., 2012). 
She presented to the emergency department with postprandial syncope and palpitations. 
Pharmacologic cardioversion was initiated by administering intravenous amiodarone (300 mg 
loading dose). Following administration, the electrocardiogram showed marked QT prolongation 
associated with ventricular arrhythmias, including an episode of torsade de pointes requiring 
immediate electrical cardioversion. When questioned about her eating habits, the patient reported 
regular GFJ consumption (≥1–1.5 L/day). After she was advised to cease drinking GFJ, the 
patient recovered and was discharged four days later. These two case reports are consistent with 
inhibition of hepatic CYP3A by GFJ when consumed regularly in copious atypical volumes 
(Lilja et al., 2000). 
 
4.1.1.2. Seville orange juice 
 
Juice prepared from the Seville (sour or bitter) orange (Citrus × aurantium L.) has been reported 
to contain furanocoumarins at concentrations comparable to GFJ (Guo et al., 2000, Malhotra et 
al., 2001). Seville orange juice has been shown to inhibit enteric CYP3A4 in vitro and in healthy 
subjects (Edwards et al., 1999, Guo et al., 2000, Malhotra et al., 2001, Penzak et al., 
2002, Mouly et al., 2005). Colchicine is an oral CYP3A substrate used to prevent gout flares and 
relieve subsequent gout attack pain (Tateishi et al., 1997). The toxicities from colchicine-CYP3A 
inhibitor interactions can lead to multiple-organ system failure. The effect of Seville orange juice 
on colchicine PK was examined in healthy volunteers (Wason et al., 2011). A single dose of 
colchicine (0.6 mg) was administered after a four day regimen of undiluted Seville orange juice 
(240 mL given twice daily). Unexpectedly, Seville orange juice decreased mean AUC of 
colchicine by 20% and delayed tmax by one hour (p < 0.0001) relative to water. The reduced 
exposure may be explained by inhibition of uptake in the intestine (see Section 4.3); however, 
colchicine has not been evaluated as a substrate for any uptake transport protein. This interaction 
is not likely to be of clinical concern, as the Seville orange is rarely consumed raw, even as juice, 
because of the extremely sour taste. The greatest use of Seville oranges as food is in the form of 
marmalade (Paine & Oberlies, 2007), but no controlled clinical studies on the effects of Seville 
orange marmalade consumption on drug disposition have been reported. 
 
Table 1. Summary of recenta controlled clinical studies involving CYP3A-mediated citrus juice–
drug interactions. 
Citrus 
juice 
Subjects (n) Administration regimen of drug and juice product (manufacturer) Change in 
mean AUC 
Reference 
Grapefruit Healthy 
volunteers (12) 
S-ketamine 0.2 mg/kg × 1 on day 5 
Normal strength (Greippi Täysmehu; Valio Ltd., Helsinki, Finland) 
Pre-treatment: 200 mL tid × 4 days 
Day 5: 150 mL with S-ketamine, 
200 mL × 2 per pre-treatment schedule 
↑ 185%b 
(p < 0.001) 
Peltoniemi 
et al., 2012 
Addison's 
disease patients 
(17) 
Cortisone acetatec 6.3 to 25 mg bid or tid per patient's prescribed 
regimen 
Normal strength (Meierienes Premium Rosa Grapefruktjuice; Tine SA, 
Oslo, Norway) 
200 mL tid with cortisone acetate × 2 days 
Day 3: 200 mL with cortisone acetate 
Cortisol: 
↑ 19%d 
(p < 0.05) 
Cortisone: 
↑ 8.6%d 
(NS) 
Methlie et 
al., 2011 
Healthy 
volunteers (20) 
Tolvaptan 60 mg × 1 
Single strength (NSP) 
240 mL × 1 with tolvaptan 
↑ 73%e 
(NC) 
Shoaf et al., 
2012 
Healthy 
volunteers (21) 
Colchicine 0.6 mg × 1 on day 4 
“Undiluted” (NSP) 
Pre-treatment: 240 mL bid × 3 days 
Day 4: 240 mL with colchicine, 240 mL × 1 per pre-treatment schedule 
↑ 2.7%b 
(NS) 
Wason et 
al., 2011 
Hyperlipidemic 
patients (130; 
arm A: 60, arm 
B: 70) 
Atorvastatin 10 to 40 mg daily per patient's prescribed regimen (arm 
A) 
Atorvastatin 5 to 20 mg daily per patient's prescribed regimen (arm B) 
Normal strength (NSP, Florida) 
300 mL with atorvastatin × 90 days 
Arm A: 
↑ 19%f 
(p < 0.05) 
Arm B: 
↓ 26%f 
(p < 0.001) 
Reddy et 
al., 2011 
Chronic 
myelogenous 
leukemia 
patients (4) 
Imatinib 400 mg daily 
Normal strength (Tropicana; Kirin, Tokyo, Japan) 
250 mL with imatinib × 7 days 
↑ 1.6%g 
(p = 0.715) 
Kimura et 
al., 2011 
Seville 
orange 
Healthy 
volunteers (23) 
Colchicine 0.6 mg × 1 on day 4 
“Undiluted” (NSP) 
Pre-treatment: 240 mL bid × 3 days 
Day 4: 240 mL with colchicine, 240 mL × 1 per pre-treatment schedule 
↓ 21% 
(SS) 
Wason et 
al., 2011 
tid, three times a day; bid, two times a day; NS, not statistically significant; NSP, not specified; NC, not 
calculated; SS, statistically significant as reflected by 90% confidence interval outside 80–125% range (i.e., no 
interaction range). 
a Published since August 2010. 
b Geometric mean AUC. 
c Cortisone acetate administered orally is converted to cortisol by hepatic 11β-hydroxysteroid 
dehydrogenase type 1. Circulating cortisol and cortisone are metabolized mainly by 5α/β-reductases, but CYP3A4 
also may contribute. 
d Median AUC. 
e n = 15. 
f Median serum concentration at day 90 relative to baseline. 
g Median peak concentration. 
 
4.1.1.3. Pomegranate juice 
 
The pomegranate (Punica granatum L.) continues as a popular ‘superfood’ touted for having 
high antioxidant content and disease prevention properties (Tzulker et al., 2007). The effect of 
pomegranate juice on CYP3A-mediated carbamazepine metabolism was studied in human liver 
microsomes and in rats; results suggested pomegranate juice inhibited intestinal, but not hepatic, 
CYP3A activity (Hidaka et al., 2005). A clinical study involving 13 healthy men given 
pomegranate juice (240 mL) and a single oral dose of midazolam (6 mg) suggested lack of 
clinical significance (Farkas et al., 2007). A more recent study involving 16 healthy Japanese 
volunteers evaluated the effect of repeated pomegranate juice consumption on the CYP3A-
mediated metabolism of midazolam (Misaka et al., 2011). Each subject was randomized to 
receive either water or a commercially available normal strength pomegranate juice (200 mL) 
twice daily for two weeks. On day 14, midazolam (15 μg/kg) was administered orally with 
pomegranate juice or water. Relative to water, pomegranate juice did not significantly alter 
midazolam PK (p = 0.40). Repeated consumption of pomegranate juice may not cause a 
clinically relevant interaction with midazolam. However, like previous clinical studies with 
pomegranate juice, no information was provided about the composition of the test juice. 
Therefore, generalizations about the enteric CYP3A inhibition potential of pomegranate juice are 
premature. 
 
4.1.1.4. Tomato juice 
 
The tomato fruit (Solanum lycopersicum L.) is consumed in many ways — raw, cooked, and in 
drinks. The antioxidant potency and purported anticancer properties are attributable to the rich 
content of lycopene, a carotene and carotenoid pigment. A recent in vitro study using 
recombinant CYP3A4 showed that tomato juice contains one or more mechanism-based and 
competitive inhibitor(s) of CYP3A4 (Sunaga et al., 2012). Ethyl acetate extracts of three 
commercially available, additive-free tomato juices (A, B, and C) and homogenized fresh tomato 
were evaluated as inhibitors of testosterone 6β-hydroxylase activity in recombinant CYP3A4. 
Relative to control (absence of extract), all four extracts at 1.5% (3.75 μL extract in 250 μL of 
incubation mixture) inhibited activity by ~70–85%; tomato juice C also inhibited nifedipine 
oxidation and midazolam 1′-hydroxylation activities by 80 and 63%, respectively. The tomato 
juice C extract showed irreversible dose- and time-dependent, as well as partial nicotinamide 
adenine dinucleotide phosphate-dependent, inhibition of testosterone 6β-hydroxylation. 
Lycopene was tested at a concentration corresponding to that in tomato juice C (110 μg/mL of 
juice) but had a modest, insignificant effect (28% inhibition). The clinical significance of 
CYP3A4 inhibition by tomato juice has not been determined. Interestingly, tomato juice has 
been studied as a ‘vehicle’ for administering granules of the proton pump inhibitor lansoprazole 
(Chun et al., 2002). Lansoprazole is metabolized by CYP2C19 and CYP3A. A randomized, four-
period crossover study involving 20 healthy volunteers compared the relative oral bioavailability 
of lansoprazole granules administered in two juices (orange juice and tomato juice, 180 mL 
each) and a soft food (strained pears, 15 mL) with that of the intact capsule (30 mg) administered 
with water (180 mL). No differences between treatments were observed, probably because the 
study was not designed to evaluate the inhibitory effect of tomato juice on CYP3A. That is, 
lansoprazole is not an established CYP3A probe substrate, and the tomato juice product was not 
characterized prior to use. The possibility of a food–drug interaction between tomato juice and 
appropriate CYP3A substrates warrants further examination in vivo. 
 
4.1.1.5. Tea 
 
Tea is the most widely consumed beverage in the world, second only to water (Dreosti, 
1996, Vinson et al., 2004). The processing technique for the leaves of the tea plant (Camellia 
sinensis (L.) Kuntze) dictates the level of fermentation and type of tea — white, green, black, 
oolong, etc. (Sang et al., 2011). Green tea undergoes minimal oxidation during processing, 
ensuring high polyphenol content (Colalto, 2010). The predominant polyphenolic compounds are 
catechins, which are presumed to prevent and/or treat cancer, cardiovascular disease, and obesity 
(Antonello et al., 2007). In addition to conventional tea infusion, concentrated green tea extract 
prepared in oral capsule form is sold as a dietary supplement and has become a popular option 
for consumers. The majority of controlled clinical studies to date evaluating the effect of 
repeated green tea administration (given as extract) on CYP activity have not demonstrated 
clinically significant interactions (Donovan et al., 2004, Chow et al., 2006). However, a recent 
case report described an ~two-fold increase in tacrolimus levels observed in a 58 year-old kidney 
transplant recipient who ingested green tea while receiving tacrolimus (Vischini et al., 2011). 
Levels decreased to within the therapeutic range after discontinuation of the tea. In vitro and 
clinical studies investigating further this potential interaction have not been published. A study in 
rats evaluating the effect of daily green tea consumption on 5-fluorouracil PK showed green tea 
(50 mg/kg for four weeks) increased the AUC of 5-fluorouracil by ~425% relative to saline 
(Qiao et al., 2011). Larger clinical studies are needed to determine the clinical significance of 
these observations. 
 
4.1.1.6. Alcoholic beverages 
 
Growing evidence supporting cardioprotective benefits promotes moderate alcohol consumption 
as part of a healthy lifestyle. Alcoholic drinks such as wine and beer can alter CYP activity via 
mechanisms that are independent of ethanol (Jang & Harris, 2007). Wine and beer are rich in 
flavonoids and other polyphenols that have antioxidant properties (Krenz & Korthuis, 2012). 
 
4.1.1.6.1. Red wine 
 
A handful of clinical drug interaction studies with red wine made from the common grape (Vitis 
vinifera L.) has been reported, but results have been inconsistent or clinically insignificant 
(Bailey et al., 2003). The magnitude of effect of red wine on the PK of CYP3A substrates may 
depend on both the amount and type of red wine consumed. Differentiating the effects of ethanol 
and wine components also poses a challenge. The red wine components trans-resveratrol (Piver 
et al., 2001) and gallic acid (Stupans et al., 2002) have been shown to inhibit hepatic CYP3A in 
vitro in a mechanism-based and non-competitive, reversible manner, respectively. However, 
studies on enteric inhibition are lacking. 
 
4.1.1.6.2. Beer 
 
Beer contains many classes of compounds, including phenolic acids, α- and β-hop acids, and 
prenylflavonoids (Vinson et al., 2003). Some of these compounds have been detected in the 
flowers of the hops plant (Humulus lupulus L.), which are used primarily for flavoring and 
preserving beer (Huvaere et al., 2003). Due to the resemblance to other plant-derived 
antioxidants and ability to inhibit CYPs that activate carcinogens, hop constituents have been 
studied for their chemopreventive properties. The prenylflavonoids isoxanthohumol and 8-
prenylnaringenin, as well as the prenylated chalcone xanthohumol, were weak inhibitors (at a 
concentration of 10 μM) of nifedipine oxidase activity in recombinant CYP3A4 (data not shown 
in publication) (Henderson et al., 2000). The inhibitory effect of a wide range of ales, lagers, 
specialty beers, ciders, and non-alcoholic lagers representative of Canadian and international 
markets was evaluated using recombinant CYP systems (Foster et al., 2009, Foster et al., 2011). 
Major α-hop acids (e.g., cohumulone, humulone, adhumulone) and β-hop acids (e.g., colupulone, 
lupulone, adlupulone) were measured in each product, and a wide variation in contents of alcohol 
and hop acids was detected. Two porter ale products (10 μL in 200 μL incubation mixture, stock 
concentration not specified) inhibited CYP3A4-mediated dibenzylfluorescein metabolism by up 
to 78%. A definitive relationship between inhibition and hops constituent levels could not be 
established. Further studies with individual compounds are warranted to support clinical 
evaluation. 
 
4.1.2. Esterase 
 
Esterases are essential to prodrugs (e.g., enalapril, lovastatin) requiring activation via hydrolytic 
cleavage of the ester bond to form the active species (Patchett, 1984, Sabra, 1988). Major 
esterases include carboxylesterase, acetylcholinesterase, butyrylcholinesterase, paraoxonase, and 
arylesterase. Inhibition of enteric esterase activity by GFJ in rats has been shown to increase 
stability of the ester in the lumen and enterocytes, resulting in higher absorption of the ester and 
higher exposure to active metabolite via rapid hydrolysis in plasma (Liederer & Borchardt, 
2006). The clinical significance of esterase inhibition by GFJ is under investigation. 
 
4.1.2.1. Grapefruit juice 
 
Clopidogrel is an oral antiplatelet prodrug that is transformed in vivo to both an inactive 
metabolite via esterases and an active form through a series of reactions mediated by CYP1A2, 
CYP2B6, CYP2C9, CYP2C19, and CYP3A4 (Kazui et al., 2010). Clopidogrel is hydrolyzed by 
esterases to an inactive carboxylic acid derivative that accounts for 85% of circulating 
metabolites in plasma (Clarke & Waskell, 2003). An ongoing clinical study (ClinicalTrials.gov 
Identifier: NCT00817999) is evaluating the impact of GFJ on clopidogrel loading and 
maintenance doses on platelet aggregation inhibition in healthy volunteers. This randomized 
two-way crossover study requires subjects to receive either water or single strength GFJ 
(325 mL) two hours prior to the loading dose (300 mg) of clopidogrel. Subjects return six hours 
after the loading dose to have platelet inhibition measured. A two-week washout period allows 
for platelet aggregation to return to baseline. The study was projected to be completed in January 
2012; results await publication. 
 
4.2. Phase II conjugation 
 
4.2.1. Uridine diphosphate glucuronosyltransferase 
 
Human glucuronosyl transferases (UGTs) facilitate elimination of endogenous substrates and 
xenobiotics by increasing hydrophilicity via formation of glucuronide conjugates (Burchell et al., 
1995). In general, the UGTs are bound to the endoplasmic reticulum, and substrate binding sites 
are exposed to the lumen (Meech and Mackenzie, 1997, Radominska-Pandya et al., 1999). UGTs 
are divided into two families, UGT1 and UGT2, which encompass more than 20 enzymes 
(Burchell et al., 1998). The identification of UGTs in human small intestine has been studied 
using a variety of approaches at different biochemical levels, from mRNA to protein to 
enzymatic activity. The expression of a relatively small number of UGTs has been confirmed in 
multiple laboratories using the same or different approaches — UGT1A1, UGT1A3, UGT1A8, 
UGT1A10, and UGT2B7 (Ritter, 2007). In contrast, analyses of several other UGTs (e.g., -1A4, 
-1A6, -1A7, -1A9, -2B4, -2B10, -2B15) have produced conflicting results, which require further 
study to be resolved. The emergence of liquid chromatography–tandem mass spectrometry 
methods for absolute protein quantification may fill in the knowledge gap (Harbourt et al., 2012). 
Intestinal UGTs can act to limit the oral bioavailability of many botanically-derived products. 
Although clinical beverage–drug interactions mediated by intestinal UGTs have not been 
reported to date, the effect of diet on UGT activity in humans is discussed, as evidence supports 
dietary and genetic effects on UGT activity in humans (van der Logt et al., 2003, Peterson et al., 
2005, Chang et al., 2007). 
 
UGT1A1 glucuronidates bilirubin, estrogens, and several dietary carcinogens (Fisher et al., 
2001). Cancer chemoprevention from dietary substances occurs partly through up-regulation of 
UGTs. Serum bilirubin, a marker of UGT1A1 activity, was shown previously to be lower among 
individuals homozygous for the UGT1A1*28 variant alleles (7/7) when randomized to a high 
fruit and vegetable diet (Chang et al., 2007). In a follow-up study, healthy men (n = 146) and 
women (n = 147) provided blood samples for genotyping and bilirubin measurements (Saracino 
et al., 2009). Multiple linear regression was used to assess relationships among UGT1A1 
genotype, bilirubin concentrations, and foods known to induce UGT activity (e.g., cruciferous 
vegetables, citrus fruits, soy foods) based on three-day eating records. A significant interaction of 
UGT1A1 genotype and citrus consumption among women was observed. Women with the 7/7 
genotype who consumed ≥0.5 daily servings of citrus fruit had ~30% lower serum bilirubin than 
those with the same genotype who consumed less. These results suggested that citrus 
consumption may increase UGT1A1 activity among women with the 7/7 genotype, potentially 
improving clearance of certain carcinogens and influencing cancer susceptibility. 
 
Chemoprevention by isothiocyanates from cruciferous vegetables occurs partly through 
induction of UGTs. In a randomized, controlled, crossover feeding trial in humans (n = 70), three 
test cruciferous-based diets were compared to a fruit-and-vegetable-free basal diet (Navarro et 
al., 2009). Subjects were genotyped (*1/*1, *1/*28, *28/*28), and serum bilirubin was measured 
to assess UGT1A1 activity. Aggregate bilirubin response to all cruciferous-containing diets was 
lower compared to the basal diet (p < 0.03 for all). For the UGT1A1*28/*28 genotype, lower 
bilirubin concentrations were noted in all cruciferous-containing diets compared to baseline 
(p < 0.02 for all). These results may have implications for altering metabolism of both 
carcinogens and drugs through dietary intervention, particularly 
among UGT1A1*28/*28 individuals. 
 
Acetaminophen (APAP) glucuronidation is believed to occur mainly by UGT1A. Evidence 
suggests that UGT2B15 also may be important. A feeding trial was conducted to assess 
UGT1A6 and UGT2B15 polymorphisms and acetaminophen conjugation in response to a 
randomized, controlled diet of selected fruits and vegetables known to induce UGTs (e.g., 
cruciferous, soy, and citrus) (Navarro et al., 2011). Subjects were genotyped 
for UGT1A1*28, UGT1A6*2, and UGT2B15*2. Healthy adults (n = 66) received APAP (1 g) on 
days 7 and 14 of each two-week feeding period. Saliva and urine were collected over 12 h. A 
modest relationship between UGT1A6, diet, and APAP conjugation was observed. Although the 
effect of the UGT2B15*2 polymorphism on APAP glucuronidation was statistically significant, 
differences in APAP glucuronidation between genotypes in response to diet were small. 
Although larger than previous controlled feeding studies designed to evaluate effects of diet on 
glucuronidation, the sample size was not powered to detect genotype–diet interactions. 
 
The inhibitory effects of commonly used herbal extracts on UGT1A4, 1A6, and 1A9 activities 
were evaluated in human liver microsomes (Mohamed & Frye, 2011). The green tea constituent 
epigallocatechin gallate (EGCG), extracted from a green tea product, inhibited UGT1A4 activity 
(IC50 = 33.8 ± 3.1 μg/mL). UGT1A4 has been detected in the intestine (Laverdière et al., 2011), 
but green tea has not been evaluated as an intestinal UGT1A4 inhibitor in vitro and in humans. 
Further studies are warranted. 
 
4.2.2. Sulfotransferase 
 
Sulfotransferases (SULTs) catalyze the sulfation of a multitude of xenobiotics, hormones (i.e., 
thyroid, estrogens), and neurotransmitters via conjugation with 3′-phosphoadenosine 5′-
phosphosulfate (Klaassen & Boles, 1997). Three human SULT subfamilies have been identified 
and detected in liver, brain, intestine, lung, kidney, and other tissues (Gamage et al., 2006). 
SULT1As are critical protectants from xenobiotics and ingested catecholamine precursors 
(Harris & Waring, 2008). Molecules such as tyrosine and dopamine are sulfated preferentially by 
SULT1A3. Grapefruit and orange juices, as well as green tea, have been shown to inhibit two 
members of the SULT1 family in vitro, SULT1A1 and SULT1A3, the latter of which is 
expressed only in extrahepatic tissues, including the intestine (Coughtrie and Johnston, 
2001, Nishimuta et al., 2005, Nishimuta et al., 2007). SULT1A inhibition prevents normal 
catecholamine deactivation. Like the UGTs, clinical food–drug interactions mediated by 
intestinal SULTs have not been reported to date, but the effect of SULT inhibitors in the diet 
(e.g., flavonoids in citrus fruits, wine, tea, chocolate) on circulating catecholamines has been 
explored. A recent analysis of 19 published human studies showed that ingestion of SULT1A 
inhibitors, such as coffee (including decaffeinated), tea, chocolate, bananas, and citrus fruits can 
elicit catecholamine increases, blood pressure changes, migraine headaches, and/or atrial 
fibrillation in susceptible individuals (Eagle, 2012). Although diet-induced SULT1A inhibition 
has been shown to have serious health consequences, the impact of concomitant drug intake on 
this complex interaction is unknown. Controlled clinical studies with appropriate SULT 
substrates are needed. 
 
4.3. Transporter-mediated efflux and uptake 
 
4.3.1. P-glycoprotein 
 
Inhibition of efflux transporters can lead to altered systemic and local drug concentrations. Due 
to the location of the efflux transporter P-glycoprotein (P-gp) on the apical (luminal) membrane 
of enterocytes (Fig. 1), substrates are extruded back into the intestinal lumen, lowering systemic 
drug concentrations (Huang et al., 2010). Thus, as with CYP3A, inhibition of enteric P-gp would 
be expected to increase systemic drug exposure. In vitro studies have demonstrated inhibition of 
P-gp activity by citrus juices, but the clinical relevance of enteric P-gp is dubious. Whether GFJ 
inhibits intestinal P-gp activity in vivo has not been fully established, largely because an ideal P-
gp probe substrate has not been identified. Several drugs transported by P-gp are metabolized by 
CYP3A as well (Benet, 2009), making it difficult to determine causality when plasma levels of a 
dual CYP3A/P-gp substrate are elevated post-GFJ ingestion. 
 
4.3.2. Organic anion transporting polypeptide 
 
The attempt to establish an in vivo probe for P-gp activity inadvertently gave rise to a new area 
of food–drug interaction studies. The initial clinical study examining effects of fruit juices on 
enteric P-gp activity using fexofenadine as a probe substrate showed an unexpected 63% 
decrease in fexofenadine AUC relative to water (Dresser et al., 2002). Mean elimination half-life 
was unchanged. This atypical interaction was attributed to inhibition of an apically located 
intestinal uptake transporter. Organic anion transporting polypeptides (OATPs) are 
transmembrane transport proteins that facilitate uptake of a number of endogenous compounds 
(e.g., bile acids, hormones) and drugs (Hagenbuch & Gui, 2008). Of the 11 human OATP family 
members, OATP1A2 and OATP2B1 have been reported to be expressed on apical membranes of 
enterocytes (Kim, 2003) (Fig. 1). Fruit juice inhibition of intestinal uptake transport has been 
reviewed (Bailey, 2010; Greenblatt, 2009), but new studies have been reported. 
 
4.3.2.1. Grapefruit juice 
 
Aliskiren is a direct renin inhibitor indicated for the treatment of hypertension. A clinical study 
of 11 healthy volunteers administered GFJ (200 mL single-strength three times daily for five 
days) and aliskiren (150 mg on day 3) showed that relative to water, GFJ significantly reduced 
mean aliskiren AUC by 61% with no change in half-life, consistent with inhibition of intestinal 
but not hepatic OATPs (Tapaninen et al., 2010). A similar study with 28 healthy subjects 
receiving 300 mg aliskiren and either water or grapefruit juice (300 mL) showed a mean AUC 
decrease of 38% by GFJ (Rebello et al., 2011). Accompanying in vitro studies in human 
embryonic kidney 293 cells expressing OATP1A2 and OATP2B1 demonstrated that aliskiren 
was not taken up in OATP2B1-expressing cells, indicating aliskiren is not a substrate for 
OATP2B1. However, uptake of [14C]-aliskiren was linear in OATP1A2-expressing cells and was 
reduced by the citrus fruit flavonoid naringin. The IC50averaged 75 μM, which is well below the 
reported range of concentrations in grapefruit juice (170 μM–6.5 mM) (Ho et al., 2000, Ross et 
al., 2000, De Castro et al., 2006, Wanwimolruk and Marquez, 2006, Brill et al., 2009), 
supporting naringin as a candidate inhibitor of intestinal OATP. The clinical impact of the GFJ–
aliskiren interaction may be minimal in view of interim results of the Aliskiren Trial in Type 2 
Diabetes Using Cardio-Renal Endpoints (ALTITUDE) (Parving et al., 2009). Safety warnings 
recommending discontinuation of aliskiren in patients with type 2 diabetes, renal impairment, 
and/or cardiovascular disease have been issued due to potential risks of renal and cardiac adverse 
events (http://www.pharma.us.novartis.com). 
 
Celiprolol is a cardioselective β-adrenergic receptor blocker that has been shown to interact with 
GFJ (Lilja et al., 2003). One of the explanations for the observed 85% decrease in mean AUC 
was inhibition of celiprolol absorption in the intestine by GFJ. An uptake study in Xenopus 
laevis oocytes injected with either OATP1A2 or OATP2B1 cRNA showed that celiprolol was a 
substrate of OATP1A2 but not OATP2B1 (Kato et al., 2009). In contrast, the authors of a more 
recent clinical interaction study hypothesized that celiprolol was transported by intestinal 
OATP2B1 (Ieiri et al., 2011), partly because the intestinal expression of OATP2B1 is higher 
than that of other OATP isoforms (Sai et al., 2006; Meier et al., 2007). Before the human study 
was initiated, the authors performed an in vitro study in OATP2B1-expressing oocytes, 
demonstrating that celiprolol was transported by OATP2B1. The potential importance of 
pharmacogenomics led the authors to evaluate the contribution of SLCO2B1 polymorphisms to 
celiprolol PK and to investigate the interaction between celiprolol and GFJ. Healthy men 
(n = 30) ingested 200 mL of GFJ three times daily for two days. On day 3, celiprolol (100 mg) 
was administered with 200 mL of GFJ. Additional GFJ (200 mL) was administered at 30 min 
and 1.5 h thereafter. The mean AUC of celiprolol was 50% lower in SLCO2B1*3/*3 (n = 4) than 
in *1/*1 (n = 5) individuals but was not deemed significant (p = 0.10). GFJ reduced mean AUC 
of celiprolol by up to 86% (p < 0.01) compared to water, but SLCO2B1*3 genotype-dependent 
differences in the PK profiles of celiprolol disappeared in the interaction phase. Although a 
population PK analysis showed SLCO2B1 status to be a statistically significant predictor of 
celiprolol PK, a larger trial is needed to confirm the clinical impact of 
the SLCO2B1*3 polymorphism. 
 
The clinical significance of the SLCO2B1*3 polymorphism has been investigated for the 
leukotriene receptor antagonist montelukast, which is prescribed to control asthma symptoms in 
adults (Mougey et al., 2009) and children (Mougey et al., 2011). In vitro experiments with 
Madin–Darby Canine Kidney Type II cells stably expressing OATP2B1 and Caco-2 cell lines 
showed that montelukast was a substrate for both OATP1A2 and OATP2B1 (Mougey et al., 
2009). The PK and PD of a single dose of montelukast with and without GFJ were evaluated in 
adolescents and young adults (15–18 years old) with asthma (Mougey et al., 2011). 
The SLCO2B1*3 polymorphism was expected to be associated with reduced absorption of 
montelukast, and co-ingestion of GFJ was hypothesized to decrease absorption of montelukast 
through inhibition of OATP2B1. Study volunteers (n = 26) were given montelukast (10 mg) with 
240 mL of either Gatorade® (control), 4× concentrated GFJ, normal-strength GFJ, or normal-
strength orange juice. A majority of the volunteers were SLCO2B1*3/*3 (n = 21), while the 
remainder was SLCO2B1*1/*3 (n = 5). GFJ, 4× GFJ, and orange juice decreased montelukast 
mean AUC by 7%, 8%, and 20%, respectively, compared to control. The reduction in mean AUC 
with orange juice co-ingestion in SLCO2B1*3/*3 individuals was considered significant 
(p = 0.032). SLCO2B1*1/*3 individuals showed a mean AUC reduction of 37% (p = 2 × 10−5) 
compared to the *1/*3 group, independent of treatment. Despite significant PK findings, neither 
genotype nor co-ingestion of citrus juice had an effect on montelukast PD (data not shown in 
publication). However, the sample size was not justified, so the study design may have lacked 
sufficient power to detect an interaction. The interpretation of montelukast-SLCO2B1 studies has 
been questioned by the manufacturer (Merck & Co., Inc.) (Chu et al., 2012). A series of in vitro 
OATP2B1-related transport experiments demonstrated that there was no direct evidence 
indicating that montelukast is a substrate of OATP2B1 or that a SLCO2B1 polymorphism alters 
montelukast uptake. OATP1A2-mediated uptake of montelukast was not discussed. Based on the 
conflicting evidence, conclusions on the direct involvement of OATP2B1 in the absorption of 
montelukast are premature, and larger trials are needed to demonstrate reproducibility of the 
clinical observations. 
 
4.3.2.2. Orange juice 
 
The sweet orange (Citrus × sinensis (L.) Osbeck) is considered fairly innocuous due to the lack 
of CYP3A-inhibiting furanocoumarins in the fruit. However, clinical studies with fexofenadine, 
certain β-blockers, and fluoroquinolones have demonstrated that orange juice can reduce 
systemic exposure by up to 83% (Neuhofel et al., 2002, Wallace et al., 2003; Lilja et al., 
2004a; Dresser et al., 2002, Lilja et al., 2005). Some of these interactions have been shown in 
vitro to involve inhibition of enteric OATP by orange juice (Dresser et al., 2002, Maeda et al., 
2007, Kato et al., 2009). The effect of orange juice on aliskiren PK and PD has been investigated 
(Tapaninen et al., 2011). In a randomized crossover study, 12 healthy volunteers ingested 
200 mL of orange juice, apple juice, or water three times daily for five days. On day 3, they 
ingested a single 150 mg dose of aliskiren. Orange juice reduced aliskiren geometric mean AUC 
by 62% relative to water while having no effect on elimination half-life. Plasma renin activity 
was increased significantly (p = 0.037) in the juice phase, but changes in blood pressure and 
heart rate were not detected. The subjects were genotyped for SLCO2B1 polymorphisms, but no 
differences in aliskiren PK between the groups were observed. As discussed previously, aliskiren 
is not a substrate of OATP2B1. The effect of orange juice on OATP1A2-mediated aliskiren 
transport has not been examined in vitro, but naringin, an ingredient in orange juice (and other 
citrus fruits), has been shown to reduce aliskiren uptake (Rebello et al., 2011). 
 
4.3.2.3. Apple juice 
 
The consumption of apples (Malus × domestica Borkh.) has been linked to reduced risk of some 
cancers, cardiovascular disease, asthma, and diabetes (Gerhauser, 2008). Main structural classes 
of apple constituents include hydroxycinnamic acids, dihydrochalcones, flavan-3-ols, flavonols, 
and triterpenoids. While there have been no in vitro and clinical studies investigating the effect 
of apple juice on drug metabolism, evidence exists that apple juice inhibits OATP activity in 
vitro and in human volunteers (Dresser et al., 2002). The following clinical studies involving 
apple juice address growing attempts to elucidate the pharmacogenomic impact of drug transport 
proteins. 
 
The effects of the SLCO2B1*3 variant (c.1457C>T) and concomitant apple juice intake on 
fexofenadine and midazolam oral PK were evaluated in a randomized crossover study of 14 
healthy volunteers (Imanaga et al., 2011). Individuals were divided based on genotype — CC 
(n = 5), CT (n = 5), and TT (n = 4). Fexofenadine (60 mg) and midazolam (5 mg) were 
administered with 300 mL of either water or normal-strength apple juice (reconstituted from 
concentrate). Additional juice was administered post-dose (150 mL every 30 min for 3 h; total 
volume = 1.2 L). When the genotyped groups were stratified in the water phase, subjects with 
CT and TT alleles showed a 37% decrease (p < 0.05) in fexofenadine mean AUC compared to 
those with CC alleles. Regardless of genotype, apple juice decreased fexofenadine mean AUC by 
79% (p < 0.05) relative to water. Neither the genotype nor the apple juice showed significant 
effects on the PK of midazolam, indicating that apple juice had minimal effect on CYP3A 
activity. OATP-mediated uptake of fexofenadine was evaluated in X. laevis oocytes expressing 
OATP2B1 and was shown to be three-fold higher (p < 0.05) than that by water-injected oocytes, 
indicating that fexofenadine was a substrate of OATP2B1. Some studies have shown that 
fexofenadine is transported by OATP2B1 (Mougey et al., 2009, Ieiri et al., 2011, Ming et al., 
2011), but others have not (Glaeser et al., 2007, Mandery et al., 2010). Although the clinical 
study results are consistent with previous findings, the impact of the OATP2B1 polymorphism is 
uncertain given the small sample size. 
 
A recently reported clinical study demonstrated that apple juice, like orange juice (Lilja et al., 
2005), reduced plasma concentrations of the β-blocker atenolol (Jeon et al., 2012). The effect of 
apple juice, as well as SLCO2B1 c.1457C>T polymorphism, on atenolol PK was determined by a 
three-way crossover study of 12 healthy volunteers. Individuals were divided based on genotype 
— CC (n = 6) and TT (n = 6). Subjects ingested atenolol (50 mg) with either water or apple juice 
(300 mL) in the first phase and additional apple juice in the second (900 mL) and third (300 mL) 
phases. Blood pressure and heart rate were measured up to 48 h after dosing. Apple juice (1.2 L) 
reduced atenolol mean AUC by up to 86% (p < 0.001). Genotype did not affect atenolol PK. No 
significant differences were observed in the hemodynamic variables. The mechanism of this 
interaction has not been elucidated. Atenolol has been identified as a substrate of OATP1A2 in 
an in vitro study of X. laevis oocytes (Kato et al., 2009), but the effect of apple juice (and orange 
juice) has not been assessed. Although no changes in PD outcomes were observed in healthy 
volunteers, the apple juice–atenolol interaction may be significant in cardiovascular disease 
patients. 
 
4.3.2.4. Tea 
 
Green tea is characterized by high concentrations of catechins, including EGCG, epicatechin 
(EC), epigallocatechin (EGC), and epicatechin gallate (ECG). The predominant catechin, EGCG, 
has been studied extensively for purported health benefits (Zaveri, 2006). The effects of the four 
catechins on OATP1A2 and OATP2B1 activity have been evaluated in vitro. Both EGCG and 
ECG at 100 μM inhibited OATP2B1-mediated estrone-3-sulfate uptake by ~70% (Fuchikami et 
al., 2006, Roth et al., 2011b), with ECG showing higher potency than EGCG (IC50 of 36 vs. 
100 μM) (Roth et al., 2011b). EGCG and ECG (both at 100 μM) also inhibited OATP1A2-
mediated estrone-3-sulfate uptake by ~75%, with ECG again showing higher potency than 
EGCG (IC50 of 10 vs. 55 μM) (Roth et al., 2011b). ECG and EGCG concentrations in brewed 
green tea average 450 μM and 430 μM, respectively, with maximum concentrations of each 
catechin in the low millimolar range (http://www.nal.usda.gov). Consumption of a cup (e.g., 
240–300 mL) or two of green tea would result in intestinal concentrations of ECG and EGCG 
within the range that inhibits OATP activity. However, the clinical significance of intestinal 
OATP inhibition by green tea has not been investigated. 
 
5. Challenges in establishing clinical significance 
 
A number of botanically-derived beverages have been shown to inhibit several intestinal CYPs 
and transporters in vitro, but many of the interactions have not translated to the clinic. These in 
vitro–in vivo discordances may be due to a lack of sufficient and/or quality data to determine a 
true positive interaction (Table 2). Although this review is focused on beverage–drug 
interactions and associated mechanisms, the proceeding concepts and recommendations for how 
to advance research strategies and standards in this field can be applied, in general, to any 
botanically-derived product–drug interactions. 
 
Table 2. Potential explanations for lack of concordance between in vitro and in vivo dietary 
substance–drug interaction studies. 
 • Lack of authentication and/or misidentification of source material 
• Inadequate description of raw materials 
• Commercially available: brand name, manufacturer, lot number, ingredients, preparation directions, 
manufacturing process, origins of growth and production 
• Freshly prepared: scientific name, quantity, plant part used, site of collection, preparation procedures, storage 
conditions 
• Adulteration of product (e.g., contamination with other substances) 
• Use of inconsistent product brand and lots 
• Insufficient analysis (e.g., physicochemical properties, biochemical activity, in vivo PK) of active constituents 
and/or metabolites in each batch being studied by a validated analytical method 
• Species differences in metabolism and transport pathways 
• Pharmacogenetic variations 
• Poorly designed in vitro experiments related to cell systems, assay conditions (e.g., enzyme/transport protein probe 
substrate(s), negative and positive controls, proper concentrations of inhibitors and/or inducers), analytical methods 
• Suboptimal clinical trial design related to an adequate number of subjects (to achieve statistical power), dietary 
restriction(s) prior to and/or during study participation, randomization, blinding, placebo, positive controls, selection 
of enzyme/transport protein probe substrate, inhibitor and/or inducer dose(s) and dosing schedule, sampling times 
• Scarce information on PK–PD relationship of dietary substance or specific active ingredients 
• Extrapolation of conclusions based on one preparation 
Adapted from Farkas and Greenblatt (2008) and Glisson and Walker (2010). 
 
Table 3. Questions to consider when reviewing clinical dietary substance–drug interaction 
studies. 
1. For a commercially available product, were the following provided — brand name, manufacturer, lot number, 
ingredients on label, preparation and storage directions, manufacturing process, origin(s) of growth and production? 
2. Were any relevant/suspected bioactive constituent(s) measured by a validated analytical method? 
3. Was the sample size justified by a power calculation? 
4. If assay sensitivity was not an issue, were the sampling times appropriate (i.e., full PK profile captured)? 
5. For single or multiple dosing of the drug or dietary substance, was the given dose a typically 
consumed/recommended/prescribed dose (i.e., reflective of ‘real world’ situations)? 
6. Were dietary restrictions imposed on the subjects during the study period? Was a diet history taken prior to and/or 
during the study period? 
7. Was pharmacogenetics considered as a source of variability? 
 
5.1. Methods to improve research practices 
 
Clinical dietary substance–drug interaction studies can be confounded easily by the documented 
variability of specific constituents (known and unknown) in individual foods. Some in vitro–in 
vivo discrepancies can be addressed simply by improved documentation of the botanical source 
material's origin(s); others may require more rigorous experimental investigation (e.g., 
discerning additive, synergistic, or inhibitory effects of constituents). Many clinical studies in the 
literature are incomplete, flawed, or superficial. Strict peer review of relevant manuscripts is 
essential to promoting best practices. A checklist of recommended questions to consider when 
evaluating submitted research articles or already published literature is listed in Table 3. Robust, 
systematic methods for evaluating potential dietary substance–drug interactions are critical, as 
one of the ultimate goals is to establish a framework for the quantitative prediction of food–drug 
interactions. 
 
5.1.1. Identification and characterization of causative ingredients 
 
A fundamental deficiency common to most dietary substance–drug interaction studies is limited 
or no descriptions of the chemical composition of the food product. The concentration of 
putative ingredients might not be sufficient to inhibit metabolism/transport in vivo (Farkas & 
Greenblatt, 2008). Since beverages are derived from single or multiple botanical sources, they 
are composed of complex mixtures of numerous phytochemical entities (Visioli et al., 2011). The 
sources and complexity of a plant's chemical constituents can contribute to batch-to-batch 
inconsistency, as concentrations of bioactive compounds can be affected by ecology, cultivation 
and manufacturing practices, storage conditions, and other environmental factors (De Castro et 
al., 2006). Thus, testing a random product in vitro and in vivo without evaluating the chemical 
makeup provides no basis for comparison between studies. Documentation and reporting of 
dietary substance characterization must be improved because many clinical studies lack thorough 
information about the test product. For commercially available products, the brand name, 
manufacturer, lot number, ingredients, preparation directions, and manufacturing process should 
be stated at minimum (Dentali, 2010). For freshly prepared material, scientific name, quantity, 
plant part used, collection site, preparation procedures, and storage conditions should be noted. 
Following verification of the test material, identification of components responsible for 
metabolism- or transport-mediated interactions poses the next challenge. 
 
Thorough characterization of constituents is a difficult but essential task, and advances in 
analytical detection technologies have improved the efficiency and sensitivity with which active 
constituents have been identified. The resulting ‘marker’ compound(s) can be used to 
authenticate the test product, serving as an indicator of quality and potency in terms of 
standardization (Smillie & Khan, 2010). Since administration of ‘standardized’ foods is not 
possible, it would be more realistic to quantify a particular known/suspected component, or 
group of components, prior to clinical use. This practice would allow some degree of between-
study comparison, as terms such as ‘normal’, ‘regular’, ‘single’, and ‘double’ strength have little 
meaning. For drug metabolism/transport purposes, a marker compound need not be unique to a 
particular product. The identity of constituent(s) should be confirmed by in vitro methods that 
screen for potential interactions. Selection of bioassay systems and associated protocols to 
quantify activity should be determined by the drug(s) and relevant phytochemical species of 
interest (Markowitz et al., 2008). Such experiments provide mechanistic information about 
inhibitory capacities, as well as specific enzymes and/or transporters involved. Two examples 
illustrating the aforementioned approach as it applies to drug metabolism and transport are 
discussed (Kim et al., 2011, Roth et al., 2011a). 
 
Conflicting results from an in vivo rat study (Uesawa & Mohri, 2006) and a clinical study (Lilja 
et al., 2007) examining the interaction between CYP3A substrates and cranberry juice (CBJ) 
prompted a systematic in vitro–in vivo approach to identify a CBJ product capable of inhibiting 
enteric CYP3A in human volunteers (Ngo et al., 2009). The effects of five CBJ products (blinded 
for in vitro experiments) were evaluated on midazolam 1′-hydroxylation activity in human 
intestinal microsomes. Each juice brand (ranging from concentrate to fresh pressed preparations) 
inhibited CYP3A activity in a concentration-dependent manner but with differing extents of 
inhibition, demonstrating that one brand is not representative of the broad marketplace. The most 
potent of these juices, CBJ ‘E’, was tested next in a proof-of-concept clinical study involving 16 
healthy volunteers. Each volunteer was administered juice E (double-strength) or water 
(240 mL × 3, separated by 15 min intervals) and midazolam (5 mg) with the third glass of 
juice/water. Relative to water, CBJ increased the geometric mean AUC of midazolam by ~30% 
(p < 0.001) while having no effect on geometric mean terminal half-life, suggesting inhibition of 
intestinal CYP3A activity. 
 
A common approach used in the natural products field to isolate therapeutically active 
ingredients, bioactivity-guided fractionation, was used to identify the CYP3A inhibitors present 
in the clinical test CBJ (Ngo et al., 2009). The juice was partitioned into hexane-, chloroform-, 
butanol-, and water-soluble fractions. Each fraction was evaluated as an inhibitor of midazolam 
1′-hydroxylation in human intestinal microsomes. The hexane- and chloroform-soluble fractions 
at 50 μg/mL were the most potent, inhibiting activity by 77 and 63%, respectively, suggesting 
that the CYP3A inhibitors resided in these more lipophilic fractions. A series of bioactivity-
guided fractionation studies with whole cranberry (Vaccinium macrocarpon Ait.) were initiated 
next to identify potential specific enteric CYP3A inhibitors in cranberry (Kim et al., 2011). 
Using human intestinal microsomes and recombinant CYP3A4, three triterpenes (maslinic acid, 
corosolic acid, ursolic acid) were isolated. IC50 values ranged from 2.8 (maslinic acid) to <10 μM 
(ursolic acid). Results suggested that these triterpenes may have contributed to the CBJ–
midazolam interaction observed clinically. The overall approach substantiated that in vitro 
characterization of dietary substances is required before initiation of clinical dietary substance–
drug interaction studies, one brand of a given dietary substance is not predictive of all brands, 
and bioactivity-guided fractionation can be used to identify specific causative bioactive 
ingredients. 
 
A bioassay-directed isolation approach was applied to the subtropical shrub aratiku (Rollinia 
emarginata Schlecht) to identify OATP modulators (Roth et al., 2011a). The stem barks of the 
shrub have been used in combination with yerba mate (Ilex paraguayensis St. Hilaire) as a 
migraine treatment and as a relaxant. Initial screening identified aratiku extract as a modulator of 
OATP-mediated transport. Fractions of the extract were screened in Chinese hamster ovary cells 
stably transfected with OATP1B1 or OATP1B3. Potential effects on OATP1B1- and OATP1B3-
mediated uptake of the two model substrates, estradiol-17β-glucuronide and estrone-3-sulfate, 
were evaluated. Although the in vitro experiments were intended for liver-specific OATPs, to the 
best of the authors' knowledge, the approach is the only one published to date that utilized 
bioactivity-guided fractionation to isolate modulators of drug uptake transporters. Ursolic acid, 
oleanolic acid, and 8-trans-p-coumaroyloxy-α-terpineol significantly inhibited estradiol-17β-
glucuronide uptake by OATP1B1 (~70% of DMSO control) but not OATP1B3. The IC50 values 
for ursolic acid and oleanolic acid were ~15 μM and ~4 μM, respectively. Ursolic acid and 
oleanolic acid modestly inhibited estrone-3-sulfate uptake by both OATPs (by up to 40% of 
control). Quercetin 3-O-α-L-arabinopyranosyl(1 → 2)α‐L-rhamnopyranoside strongly inhibited 
OATP1B1- and OATP1B3-mediated uptake of estradiol-17β-glucuronide (by >95%). However, 
OATP1B3-mediated uptake of estrone-3-sulfate was stimulated. The thorough descriptions of 
the starting material, preparation procedures, analytical methods, and bioassay system protocols 
were strengths of the work. The overall method illustrated the efficiency of bioassay-guided 
isolation to identify selective transporter modulators in a botanical that has not been studied 
clinically. Interestingly, ursolic acid also was identified in the CBJ product mentioned 
previously. Such information permits assumptions about which drugs may interact with a food 
containing ursolic acid (e.g., apple, cranberry, pear, plum, olives) (Aggarwal and Shishodia, 
2006, He and Liu, 2006, Allouche et al., 2009, Guinda et al., 2010). 
 
Identification and thorough characterization of a particular dietary substance do not change 
immediately certain research practices. Since the establishment of furanocoumarins in GFJ as 
unequivocal mediators of enteric CYP3A-based interactions in 2006 (Paine et al., 2006), only a 
handful (n < 10) of clinical studies involving CYP3A substrates has reported furanocoumarin 
content in the test juice. Furanocoumarins have been studied to the extent that they can be 
considered marker compounds. Characterization of a given GFJ in terms of furanocoumarin 
content could be used to predict the likelihood and magnitude of an interaction 
(see Section 5.1.4). Between-study comparisons also can be made. A basic, yet overlooked, 
solution to establishing meaningful physiological dose–response relationships for dietary 
substances is to characterize the product prior to use. The information gained will inform the 
nature and extent of follow-up in vitro and in vivo interaction studies. 
 
5.1.2. Appropriate design of in vitro and in vivo food–drug interaction studies 
 
The regulation (or lack thereof) of dietary substances in the United States is different from drugs. 
Although dietary substances are regulated as food (Abdel-Rahman et al., 2011), bioactive 
compounds in these substances can act like drugs (i.e., cure, mitigate, treat, or prevent disease). 
Since it is unlikely that legislation will change to require more intense drug–dietary substance 
interaction studies, individuals in the field can take a cue from the pharmaceutical industry and 
adopt some or all recommendations made in the FDA's guidance on drug–drug interaction 
studies (http://www.fda.gov/cder/guidance) to create a more consistent evaluation approach. 
Methods and decision trees in the guidance on botanical drug products (Chen et al., 2008) pale in 
comparison. As stated previously, the experimental design aimed to quantify activity of a dietary 
substance should be determined by the drug(s)/probe substrate(s) and relevant phytochemical 
constituent(s) of interest. Data generated from well-designed in vitro studies (e.g., Km, Vmax, Ki, 
IC50 determinations), combined with clinical PK information, may serve as a screening 
mechanism to rule out the need for additional in vivo studies, or provide a mechanistic basis for 
proper design of clinical studies using a modeling and simulation approach (see Section 5.1.4). 
 
5.1.3. Development and validation of pharmacokinetic–pharmacodynamic relationships 
 
Pharmacodynamic consequences of dietary substance–drug interactions are underexplored 
aspects of controlled clinical PK studies. Selection of one or more clinically relevant PD 
measures begins with a drug of interest for use in a target patient population. Most PD endpoints 
are surrogates that correlate with clinical efficacy and are assessed in multiple dosing studies 
conducted over a period of more than one week or months. For example, antihypertensive drug 
trials measure blood pressure, antihistamine studies measure skin wheal formation, antiviral 
agent studies measure viral load, and opioid analgesic trials record pain scores (efficacy) and 
pupil diameter (toxicity) (Derendorf & Hochhaus, 1995). Depending on the therapeutic drug 
category, some PD measures have been validated over time and are well-accepted surrogates for 
drug efficacy and toxicity. Most food–drug interaction trials involve single dosing of healthy 
volunteers, who may exhibit different PK and PD outcomes compared to diseased patients. More 
studies in patient populations are needed to determine the short- and long-term responses to 
dietary substance–drug interactions. 
 
A recent study with GFJ and atorvastatin demonstrated the importance of measuring PD 
outcomes and cautious extrapolation of conclusions from short term, healthy subject trials to the 
actual clinical setting of drug-treated patients (Reddy et al., 2011). Previous healthy volunteer 
studies have shown that large quantities (200–250 mL three times daily for ≥two days) of GFJ 
increase exposure to atorvastatin by up to three-fold (Lilja et al., 1999, Fukazawa et al., 
2004, Ando et al., 2005). The Grapefruit Effect on Atorvastatin Therapy (GREAT) trial 
evaluated the effects of a typical daily single ‘dose’ of GFJ on plasma concentrations and lipid-
lowering effects of atorvastatin in hyperlipidemic patients on a stable atorvastatin regimen 
(>90 days) (Reddy et al., 2011). Patients receiving extended treatment with atorvastatin (10, 20 
or 40 mg daily) at a stable dose were randomized to two arms and received normal strength GFJ 
(300 mL daily) for 90 days. One cohort (Arm A, n = 60) continued on their current dose of 
atorvastatin; the other cohort (Arm B, n = 70) reduced the daily dose by half to confirm the need 
for atorvastatin dosage reduction while on GFJ. Serum atorvastatin, lipid profile, liver function, 
and creatine phosphokinase (to monitor for muscle toxicity) were measured at baseline and at 30, 
60, and 90 days after starting GFJ. A statistically significant increase (19–26%) in median serum 
atorvastatin concentration was observed in Arm A, but changes in lipid profile were negligible. 
No adverse effects in liver or muscle were evident. Arm B showed a decrease (12–25%) in 
median serum atorvastatin with a small but statistically significant unfavorable serum lipid 
profile (i.e., increased cholesterol, triglycerides, low-density lipoprotein). No adverse effects on 
liver function tests or creatine phosphokinase were observed. Although the study results 
suggested chronic GFJ co-ingestion with atorvastatin is safe, several considerations should be 
noted. First, the lipid profile of the study population at baseline (i.e., already on stable dose of 
atorvastatin) was reasonably controlled, so the addition of GFJ might have been minimally 
effective. Patients newly prescribed atorvastatin may have a different outcome; that is, 
concomitant GFJ may improve the lipid profile more rapidly and/or to a greater extent than in 
patients stabilized on atorvastatin. Second, the lack of effect on lipids may have been due to 
insufficient furanocoumarin content in the test juice; the increase in atorvastatin exposure was 
modest. Furanocoumarin content in the test GFJ was not reported, and whether it was measured 
is unclear. Third, the 100% Florida GFJ used in the study was from one lot and was tested for 
uniformity and nutritional content (e.g., sugar, total carbohydrate, vitamin C). It is possible that 
the daily intake of carbohydrate and sugar in the GFJ offset some of the clinical benefit. 
 
The aforementioned study highlights the importance of designing clinical studies that reflect 
typical eating/drinking habits. The study also draws attention to the potential use of dietary 
substances as ‘PK boosters.’ Indeed, deliberate inhibition of enteric CYP3A by GFJ consumption 
and/or individual components has been used by the scientific community for both therapeutic 
and pharmacoeconomic purposes. For example, this strategy has been evaluated and suggested to 
be beneficial to patients undergoing treatment for cancer and organ transplantation. Oral 
bioavailability would be increased without GFJ itself exerting additional adverse effects. Costs 
and side effect severity of these multi-drug and toxic regimens could be reduced through dose 
and/or dosing frequency reduction by coadministration with GFJ. The tyrosine kinase inhibitor 
imatinib, as well as the immunosuppressants sirolimus and tacrolimus, have been investigated 
clinically (Cohen et al., 2009, Liu et al., 2009, Kimura et al., 2011). A deficiency common to all 
the studies is the lack of phytochemical analysis of the juice. The clinical trial investigating the 
effect of GFJ on sirolimus PK in advanced solid tumor patients initially showed no effect of GFJ, 
which was attributed to insufficient furanocoumarin content in the selected GFJ. A more ‘potent’ 
GFJ containing (unreported) inhibitory concentrations of furanocoumarins increased plasma 
sirolimus concentrations by up to 400% relative to water. The clinical study evaluating the effect 
GFJ on imatinib PK in Japanese men diagnosed with chronic myelogenous leukemia showed no 
effect; furanocoumarin content in the GFJ was not measured. The lack of effect in the imatinib 
study could be attributed to the same reason a lack of effect was observed initially in the 
sirolimus study. A recent study in rats suggested that GFJ may be equally effective as ritonavir in 
increasing the bioavailability of the HIV protease inhibitor lopinavir (Ravi et al., 2012). Again, 
like the aforementioned studies, the GFJ was not analyzed for furanocoumarin content. In 
addition, translation of this interaction to the clinical setting has not been determined. 
Phytochemicals (e.g., green tea catechins) capable of inhibiting efflux transporters have been 
studied with anti-tumor agents as multidrug resistance-reversing co-therapies (Asensi et al., 
2011, Wu et al., 2011). Long-term safety and pharmacoeconomic impact of combining drugs and 
dietary substances have not been evaluated sufficiently to change current disease management. 
 
PD-related conclusions are unwarranted due to insufficient data on the PK relationship between 
the causative ingredient(s) and the drug(s). A rigorous evaluation of a PK–PD relationship can be 
achieved by applying in silico methods to in vitro and in vivo data. Modeling and simulation 
techniques permit the prediction of a potential interaction, but extensive in vitro data (e.g., 
physicochemical properties, ADME parameters) and clinical PK information (including external 
datasets for validation) are imperative. 
 
5.1.4. Prediction of food–drug interactions 
 
PK–PD modeling and simulation have become powerful, integral tools for improving the 
efficiency of the drug development process, and the value of these approaches has been 
championed in several reviews (Gobburu and Marroum, 2001, Chien et al., 2005, Miller et al., 
2005, Holford et al., 2010). The (patho)physiology of biological systems and the pharmacology 
of treatments acting on these systems can be modeled to predict quantitatively the dose–response 
relationship. Similar principles can be applied to dietary substances, especially in relation to how 
they interact with drugs. A quantitative analysis of both in vitro and clinical PK data is 
accomplished by a variety of algorithms and models (e.g., basic, mechanistic, static, or dynamic) 
(Einolf, 2007). The application of physiologically-based pharmacokinetic (PBPK) modeling to 
drug development has evolved over the past 10 years, reflecting significant advances in the 
predictability of key PK parameters from in vitro and in vivo data and in the availability of 
specialized software (e.g., GastroPlus, Simcyp, Berkeley-Madonna, MATLAB-simulink) (Pang 
and Durk, 2010, Poulin et al., 2011, Rowland et al., 2011, Zhao et al., 2011, Bouzom et al., 
2012). Framing the right question and capturing key assumptions are essential to delivering 
meaningful results. For the purpose of this review, modeling and simulation strategies as they 
apply to the quantitative prediction of CYP3A-mediated oral DDIs are discussed. Lessons from 
these approaches can be applied to dietary substance–drug interactions to establish a framework 
for the quantitative prediction of such interactions (Table 4). 
 
Table 4. General framework for quantitative prediction of dietary substance–drug interactions 
involving CYP inhibition as a major underlying mechanism. 
PBPK modeling toolsa acslX, MATLAB-simulink, ADAPT, Berkeley-Madonna, MCSIM, SAAM 
II, GastroPlus, PK-Sim, Simcyp 
1. Characterization of physicochemical propertiesb of drug 
and phytochemical inhibitor 
pKa, log P, fu plasma, B/P ratio, Peffc, solubilityc 
2. Identification and quantification of clearance pathway(s) 
based on in vitro and/or in vivo studies 
- Liver/intestine/kidney/etc.: CYP, non-CYP, transport 
Km, Vmax, Clint, Ki 
fm 
kinact, kdeg, ksyn 
3. Model-building based on information from Steps 1 and 2 Physiological parameters: organ blood flows, tissue partition coefficients (Kp)b 
Scaling factors (microsomes, primary cells ➔ organ) 
4. Simulation of plasma concentration–time profile(s) of drug Cmax, AUC, Cl, Cl/F, t½ 
5. Comparison of simulated plasma concentration–time 
profile(s) with observed in vivo PK data 
Visual predictive checks 
Prediction fold-error 
6. Model refinement based on comparison of estimated 
parameters with those obtained from in vivo PK 
- Conduct sensitivity analysis if necessary 
 
7. Simulation of plasma concentration–time profile(s) of 
phytochemical inhibitor 
Cmax, AUC, Cl, Cl/F, t½ 
8. Comparison of simulated plasma concentration–time 
profile(s) with observed in vivo PK datad 
Visual predictive checks 
Prediction fold-error 
9. Model refinement based on comparison of estimated 
parameters with those obtained from in vivo PK 
 
10. Simulation of plasma concentration–time profile(s) of 
drug with phytochemical inhibitor 
Drug: AUCi/AUC 
B/P, blood to plasma ratio; Clint, intrinsic clearance; fm, fraction metabolized; fu, fraction unbound in 
plasma; Peff, effective intestinal permeability; kdeg, rate of degradation, kinact, rate of inactivation; ksynth, rate of 
synthesis; Cl/F, apparent oral clearance; AUCi/AUC, ratio of drug AUC in presence of inhibitor to AUC 
without inhibitor. 
a Not all-inclusive list. 
b Measured experimentally or predicted using software. 
c BCS/BCDDS classification. 
d Not always measurable. 
 
The utility and accuracy of in vitro CYP inhibition data in the prediction of in vivo DDIs have 
been examined in numerous works with varying degrees of success (Galetin et al., 2005, Galetin 
et al., 2006, Obach et al., 2005, Obach et al., 2006, Obach et al., 2007, Houston and Galetin, 
2008, Fahmi et al., 2008, Fahmi et al., 2009, Youdim et al., 2008, Obach, 2009, Fan et al., 
2010, Hisaka et al., 2010Bruyère et al., 2010;Boulenc and Barberan, 2011, Guest et al., 
2011, Shardlow et al., 2011). Most of the cited predictive models are related to hepatic CYP3A-
mediated interactions since they are well-characterized and >50% of marketed pharmaceutical 
agents are CYP3A substrates, allowing for validation. However, models have been modified to 
incorporate the contribution from the intestine, as studies demonstrated that inhibition 
of both hepatic and intestinal metabolism was needed for an improved DDI prediction (Galetin et 
al., 2007, Galetin et al., 2008, Galetin et al., 2010, Yang et al., 2007, Peters, 2008, Gertz et al., 
2010, Gertz et al., 2011, Tachibana et al., 2010, Tachibana et al., 2012). PBPK modeling is used 
extensively, and such a data-driven method relies on extensive information on the 
victim and precipitant drugs — physicochemical properties, intestinal permeability, organ 
clearance processes, etc. The difficulty with dietary substances is the paucity of research on their 
oral bioavailability, metabolic mechanisms, human PK, and concentrations achieved at the site(s) 
of action. Despite the challenges, evaluation of a suspected dietary substance–drug interaction is 
possible, and one particularly relevant to this discussion is described (Fenneteau et al., 2010). 
 
Furanocoumarins in GFJ have been studied extensively over the past two decades as inhibitors of 
CYP3A4 (intestinal and hepatic, although the latter is less relevant). Bergamottin and 6′,7′-
dihydroxybergamottin (DHB) are typically the most abundant furanocoumarins present in GFJ 
and have been proposed as major intestinal CYP3A4 inhibitors contributing to GFJ–drug 
interactions (Kakar et al., 2004, Paine et al., 2004, Uesawa et al., 2011). These compounds have 
been characterized to the extent that they can be considered ‘marker’ compounds. Quantification 
of a given juice in terms of furanocoumarin content could be used to predict the likelihood and 
magnitude of an interaction with a CYP3A substrate and make between-study comparisons. 
Modeling and simulation can be used to validate one or more marker furanocoumarins as 
predictors of an interaction. As discussed previously, given the possibility of using GFJ and/or 
individual constituents as a ‘drug-sparing, PK-boosting agent’, a standardized approach to 
evaluate quantitatively GFJ–drug interactions is imperative for the proper clinical management 
of patients. 
 
A PBPK modeling approach was used to predict the impact of inhibiting intestinal and hepatic 
metabolism on human PK of CYP3A substrates (Fenneteau et al., 2010). One of the inhibitors of 
interest was DHB, which was given in the form of GFJ in two clinical studies (Kupferschmidt et 
al., 1995, Lilja et al., 2004b). The objective was to predict the PK of simvastatin and midazolam 
in the presence of DHB in humans. A model was developed (software not specified) to account 
for absorption (gut), distribution, and hepatic clearance of the substrates and DHB. An important 
set of data to calculate parameters related to those processes is physicochemical properties of the 
drugs and DHB. Molecular structure, solubility, and permeability properties have been used to 
develop in silico models that allow the early estimation of several ADME properties. 
Commercial ADME software programs are reviewed elsewhere (van de Waterbeemd & Gifford, 
2003). Inhibitory parameters of DHB (i.e., Ki and kinact) measured in human intestinal 
microsomes and unbound DHB concentration in human intestinal microsomes were incorporated 
into the model. Because no plasma concentration–time profile of DHB was available (or 
detectable), the concentration of DHB in the gut membrane was simulated using the PBPK 
model. For the simulations, the authors assumed a DHB amount of 43 μmol. Interestingly, DHB 
was not measured in either of the GFJs used in the clinical studies. Nevertheless, the resulting 
profile was used to predict the inhibitory effect of GFJ on midazolam and simvastatin PK. AUC 
and maximum plasma concentration (Cmax) were predicted successfully within a two-fold error 
range either in the absence or presence of DHB. This PBPK study was the first to investigate the 
impact of an inhibitory food ingredient on drug PK. Additional studies with other substrates 
would validate this approach. Once validated, the techniques can be applied to other food 
ingredients. Although the aforementioned study was specific to CYP3A, it is important to note 
that food and substances in food can inhibit both uptake and efflux transporters in the intestine; 
the final result on drug bioavailability will depend on the more important contributor to 
absorption. Furthermore, the interplay between CYPs and transporters in dietary substance–drug 
interactions is recognized (Benet et al., 2003); thus, incorporation of more complex processes 
will require more detailed data. Literature examples for modeling/predicting intestinal 
transporter-mediated interactions are few (Bolger et al., 2009, Fan et al., 2010). 
 
In summary, whole body physiology is described by a series of linked mathematical equations 
with model parameters corresponding to measurable quantities, such as blood flow rates and 
tissue volumes. In vitro data relevant to drug absorption, distribution, metabolism, and excretion 
are scaled to in vivo scenarios. The new FDA guidance on DDI studies emphasizes the use of 
modeling and simulation to streamline the development process. Although such an approach is 
not required of those in the food/dietary supplement industries, modeling and simulation of new 
drug candidates and known dietary ingredients should be undertaken. This approach may rectify 
a considerable amount of work that may otherwise be inconsistent, contradictory, and 
irreproducible. 
 
6. Conclusions 
 
Interactions between medications and dietary substances, as foods or supplements, remain a 
relatively understudied and misunderstood area of pharmacotherapy. The upward trend of 
polypharmacy and ever-increasing consumer perception, rather misconception, of “all-natural” 
(i.e., safe) remedies from dietary supplements and so-called ‘superfood’ sources has contributed 
to the potential for dangerous interactions. Although significant progress has been made in 
understanding mechanisms of intestinal inhibition by CYPs and efflux/uptake transport proteins, 
questions remain. Results from in vitro studies have not always translated to the clinic; these in 
vitro–in vivo discordances may be due to a lack of well-designed, proof-of-concept studies that 
control for as many confounding factors as possible. The complex nature of dietary substances 
and lack of adequate characterization preclude between-study comparisons, as well as accurate 
predictions of drug interaction liability. Since no ‘standard’ system exists to predict the effect of 
dietary substances on drug disposition, researchers in the field can model their scientific 
approach after that used in drug development. The integration of data from in vitro, in vivo, and 
in silico studies can optimize study designs and clarify the potential risks of inhibition of 
intestinal metabolism/transport by a given dietary substance on pharmacotherapeutic outcomes. 
Such an aggressive assessment requires a multidisciplinary collaboration of experts from several 
fields, including clinical pharmacologists, pharmacognosists/natural products chemists, and 
botanists (Dentali, 2010, Gurley, 2010). The ultimate goal is to develop practice guidelines to 
provide a consistent approach in managing drug–dietary substance interactions appropriately. 
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